clofarabine + etoposide + cyclophosphamide + pegaspargase + vincristine

This is a multi-agent chemotherapy combination consisting of **clofarabine**, **etoposide**, **cyclophosphamide**, **pegaspargase**, and **vincristine**, primarily studied and used in clinical settings for relapsed or refractory acute lymphoblastic leukemia (ALL), and in some cases for relapsed/refractory acute myeloid leukemia (AML), especially prior to hematopoietic stem cell transplantation. - **Clofarabine**: a nucleoside analog that inhibits DNA synthesis, repair, and ribonucleotide reductase, leading to apoptosis of rapidly dividing cells. - **Etoposide**: a topoisomerase II inhibitor that causes DNA strand breaks, ultimately leading to cell death. - **Cyclophosphamide**: an alkylating agent that crosslinks DNA, disrupting replication and transcription. - **Pegaspargase**: a pegylated L-asparaginase enzyme that depletes asparagine, an amino acid necessary for leukemic cell survival, by converting it to aspartic acid and ammonia. - **Vincristine**: a vinca alkaloid that inhibits microtubule formation in mitotic spindles, causing cell cycle arrest at metaphase. This combination leverages different mechanisms targeting leukemic cells at various cell cycle phases and metabolic dependencies. While some combinations with the first three agents (clofarabine, etoposide, cyclophosphamide) have been more extensively studied, combinations including pegaspargase and vincristine are consistent with intensification regimens in relapsed ALL and are used off-label or in specific clinical protocols[1][3][5][6].